"However, this strength will not necessarily translate into support for the country's pharmaceutical market, which is facing challenges on a number of fronts, not least the government's attempt to constrain expenditure on healthcare and medicines.Combined with factors such as patent expirations, the above situation is forecast to translate into a contraction of pharmaceutical market values in Austr" . . . .